AU1680292A - Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen - Google Patents

Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen

Info

Publication number
AU1680292A
AU1680292A AU16802/92A AU1680292A AU1680292A AU 1680292 A AU1680292 A AU 1680292A AU 16802/92 A AU16802/92 A AU 16802/92A AU 1680292 A AU1680292 A AU 1680292A AU 1680292 A AU1680292 A AU 1680292A
Authority
AU
Australia
Prior art keywords
antiandrogen
treatment
reductase inhibitor
pharmaceutical combination
prostatic cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16802/92A
Inventor
Glenn J Gormley
Elizabeth Stoner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU1680292A publication Critical patent/AU1680292A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
AU16802/92A 1991-03-20 1992-03-19 Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen Abandoned AU1680292A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US672506 1984-11-19
US67250691A 1991-03-20 1991-03-20
US84615492A 1992-03-11 1992-03-11
US846154 1992-03-11

Publications (1)

Publication Number Publication Date
AU1680292A true AU1680292A (en) 1992-10-21

Family

ID=27100764

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16802/92A Abandoned AU1680292A (en) 1991-03-20 1992-03-19 Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen

Country Status (5)

Country Link
AU (1) AU1680292A (en)
IE (1) IE920878A1 (en)
IL (1) IL101245A0 (en)
PT (1) PT100255A (en)
WO (1) WO1992016233A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012398A1 (en) * 1993-11-04 1995-05-11 Merck & Co., Inc. 7-substituted-4-aza-steroid derivatives as 5-alpha- reductase inhibitors
WO1993023419A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. NEW 7β-SUBSTITUTED-4-AZA-5α-CHOLESTAN-ONES AS 5α-REDUCTASE INHIBITORS
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
IL111467A0 (en) * 1993-11-12 1994-12-29 Merck & Co Inc Pharmaceutical compositions comprising 7 beta -substituted -4-aza 5 alpha -cholestan-3-ones and 5 alpha reductase 1 inhibitors
US5525608A (en) * 1994-04-20 1996-06-11 Merck & Co., Inc. 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
US5817818A (en) * 1994-09-16 1998-10-06 Glaxo Wellcome Inc. Androstenones
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5763361A (en) * 1995-10-23 1998-06-09 Merck & Co., Inc. 17-alkyl-7-substituted-4-aza steroid derivatives as 5-α-reductase inhibitors
US6054432A (en) * 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684635A (en) * 1984-05-11 1987-08-04 Norman Orentreich Compositions and methods for inhibiting the action of androgens
HU223662B1 (en) * 1989-07-07 2004-11-29 Endorecherche Inc. Combination compositions having alpha-reductase inhibitor suitable for preventing and/or treating benign prostatic hyperplasia, kits and process for producing them
AU5851690A (en) * 1989-07-07 1991-02-06 Endorecherche Inc. Method of treatment of androgen-related diseases

Also Published As

Publication number Publication date
IL101245A0 (en) 1992-11-15
PT100255A (en) 1993-09-30
WO1992016233A1 (en) 1992-10-01
IE920878A1 (en) 1992-09-23

Similar Documents

Publication Publication Date Title
SG80530A1 (en) Pharmaceutical combination for the treatment of prostatic hyperplasia, containing a 5 alpha-reductase inhibitor and an antiandrogen
GB2262229B (en) Pharmaceutical compositions of pH at least 8 comprising an HMG-CoA reductase i nhibitor
PH30794A (en) Inhibition of phosphatidylinositol 3-kinase with worthmannin and analogs thereof.
HU9303218D0 (en) Application of atp-depended protease and its inhibitor for treatment of cachexy and amyotrophia
AU1893492A (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
AU5590596A (en) Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
AU1680292A (en) Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen
AU3942893A (en) Total synthesis of taxol
AU2265895A (en) Inhibition of liver cancer by the use of gnrh and gnrh analogs
HU9302347D0 (en) Application of quinones for treatment of cancer and/or aids
AU8132294A (en) Total synthesis of taxol and analogues thereof
GB9226832D0 (en) Pharmaceutical preparations for the treatment of psoriasis
IL101410A0 (en) Formulation for the treatment of cancer
AU8074294A (en) Rapid synthesis and use of 18f-fluoromisonidazole and analogs
NO961226L (en) Compounds for the prevention and treatment of viral-induced tumors
AU4532893A (en) Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
IL111467A0 (en) Pharmaceutical compositions comprising 7 beta -substituted -4-aza 5 alpha -cholestan-3-ones and 5 alpha reductase 1 inhibitors
EP0733365A3 (en) Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer
AU2202792A (en) Specific inhibition of dihydrofolate reductase and compounds therefor
AU5957794A (en) Compositions and method for the inhibition of phagocytes
EP0644716A4 (en) Medical uses of trioxolane and diperoxide compounds.
AU4825993A (en) New compounds for use in the treatment of cancer
AU7041194A (en) Use of 12-deoxyphorbol 13-monoesters for inhibiting neoplasia and tumor promotion
AU1192495A (en) Use of selegiline and its derivatives for the treatment of psoriasis
HU0000790D0 (en) Stabilized medicaments containing hmg-coa reductase inhibitor and process for producing them